title: Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients.
abstract: OBJECTIVE
  To evaluate the effect of nasogastric lansoprazole on acid suppression in critically ill patients.
  
  
  METHODS
  Patients were eligible for the study if they had a nasogastric tube in place and had not received acid-suppressive agents for 3 days prior to enrolment into the study. Patients with active gastrointestinal bleeding or a baseline gastric pH > 4.0 were excluded. Patients served as their own controls during a 24 h lead-in period. Lansoprazole 30 mg was administered once daily with water through a nasogastric tube for 2 days. Intragastric pH was measured by continuous 24 h pH-metry for 3 days.
  
  
  RESULTS
  Fifteen patients were enrolled into the study. The baseline median 24 h intragastric pH was 2.25 +/- 1.01, and increased to 6.70 +/- 0.82 (P= 0.001) after 2 days of lansoprazole. Mean percentage of time intragastric pH was > or = 4.0 was 25 +/- 13% at baseline, and increased to 84 +/- 14% (P=0. 001) after 2 days of lansoprazole.
  
  
  CONCLUSIONS
  Nasogastric lansoprazole 30 mg daily is effective in suppressing gastric acid secretion in critically ill patients.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China. tsaiwl@vghtc.vghtc.gov.tw
authors.forename: W L
authors.initials: WL
authors.lastname: Tsai
authors.forename: S K
authors.initials: SK
authors.lastname: Poon
authors.forename: H K
authors.initials: HK
authors.lastname: Yu
authors.forename: C S
authors.initials: CS
authors.lastname: Chang
authors.forename: H Z
authors.initials: HZ
authors.lastname: Yeh
authors.forename: C W
authors.initials: CW
authors.lastname: Ko
authors.forename: G H
authors.initials: GH
authors.lastname: Chen
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016638:Critical Illness; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007441:Intubation, Gastrointestinal; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole